Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements using Radiomics

Multimodality imaging measurements of treatment response are critical for clinical practice, oncology trials, and the evaluation of new treatment modalities. The current standard for determining treatment response in non-small cell lung cancer (NSCLC) is based on tumor size using the RECIST criteria. Molecular targeted agents and immunotherapies often cause morphological change without reduction of tumor size. Therefore, it is difficult to evaluate therapeutic response by conventional methods. Radiomics is the study of cancer imaging features that are extracted using machine learning and other semantic features. This method can provide comprehensive information on tumor phenotypes and can be used to assess therapeutic response in this new age of immunotherapy. Delta radiomics, which evaluates the longitudinal changes in radiomics features, shows potential in gauging treatment response in NSCLC. It is well known that quantitative measurement methods may be subject to substantial variability due to differences in technical factors and require standardization. In this review, we describe measurement variability in the evaluation of NSCLC and the emerging role of radiomics. © 2019 Wolters Kluwer Health, Inc. All rights reserved

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival

[Background/Purpose]To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. [Methods]Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study). [Results]A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4). [Conclusions]Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy

Low dose chest CT protocol (50mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality

AbstractPurposeTo determine the diagnostic capability of low-dose CT (50mAs) in comparison to standard-dose CT (150mAs).Materials and methodsFifty-nine consecutive patients underwent two non-contrast chest CT scans with different current-time products (50 and 150mAs at 120kVp) on a 64-detector row CT scanner. Three board certified chest radiologists independently reviewed 118 series of 2mm-thick images (2 series for each of 59 patients) in a random order. The readers assessed abnormal findings including emphysema, ground-glass opacity, reticular opacity, micronodules, bronchiectasis, honeycomb, nodules (>5mm), aortic aneurysm, coronary artery calcification, pericardial and pleural effusion, pleural thickening, mediastinal tumor and lymph node enlargement. Five-point scale from 1 (definitely absent) to 5 (definitely present) was used to record the results. The rates of score agreement between two images were calculated. Deviation of one observer's score from other two observers was compared between low dose CT and standard dose CT.ResultsMean agreement rate of the lung parenchymal findings between low dose CT and standard dose CT images was 0.836 (range, 0.746–0.926). Mean agreement rates for mediastinal and pleural findings were 0.920 (range, 0.735–1.000). There was no statistically significant difference in the deviation of the observers' scores between low-dose CT and standard-dose CT.ConclusionLow dose CT protocol at 50mAs can produce the screening results consistent with standard dose CT protocol (150mAs), supporting routine use of low dose chest CT protocol

Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterization—iLEAD study

Objective: To determine the lesion characterization capability by low dose CT for localized lung lesions in comparison with standard dose CT. Subjects and methods: Approval for this study was granted by our Institutional Review Board. Fifty-two consecutive patients (36 males and 16 females, median age of 71 years.) who had CT examinations for evaluation of lung lesions comprise the study population. Two chest CT scans were performed with current time product of 50 and 150 mAs at 120 kVp, with the same scan length with a 16 detector-row CT scanner. Three readers evaluated 52 target lesions and assigned an overall impression score to each target lesion, using a 5 point scale from 1 (definitely benign) to 5 (definitely malignant). Six features of the lesions including lesion type, margin characteristics, calcification, lobulation, speculation, and pleural indentation were also reported with 5-point scales. The weighted kappa analyses and receiver operating characteristic analysis were used for analysis. Results: The mean kappa value between low-and standard-dose CT was 0.82 for overall impression of the lesions, showing almost perfect agreement. Area under the curve of low-dose CT (Az = 0.74) had no significant difference from that of standard-dose CT (Az = 0.74) (p = 0.61). The kappa values for six lesion features ranged from 0.45 to 0.83, showing moderate to almost perfect agreement. Conclusion: Lesion characterization capability by low-dose CT images was comparable to that by standard-dose CT images and therefore sufficient for evaluation of localized lung lesions. Keywords: Radiation dose reduction, Lung nodules, Lung masses, Chest C

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival

[Background/Purpose]To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. [Methods]Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study). [Results]A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4). [Conclusions]Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy